Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Ruxolitinib cream for children ages 6 to 11
Official title: A Phase 3, Randomized, Double-Blind, Efficacy, and Safety Study of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Status: Recruiting now
Description:
This Phase 3 study is evaluating the safety and efficacy of ruxolitinib cream in children ages 6–11 with nonsegmental vitiligo.
During the first 24 weeks, participants receive one of two strengths of ruxolitinib cream or a matching cream (called "vehicle") with no active medicine. Study cream is applied twice daily.
Participation continues for up to 52 weeks, followed by a safety follow-up.
Basic eligibility includes measurable nonsegmental vitiligo on the face and body: at least 0.5% of body surface area on the face and at least 3% on nonfacial areas, with no more than 10% total body involvement. Other criteria apply, including requirements concerning current and recent vitiligo treatments.
Sites are located in Argentina and 13 European countries. There are no U.S. or Canadian sites. The research site determines eligibility. Use of ruxolitinib cream for vitiligo in this age group is investigational.
Related pediatric study: View the study for children ages 2–11 in the United States and Canada
Start date: November 13, 2025
Completion date: December 01, 2027
Organizer: Incyte Corporation
Contact: Incyte Corporation Call Center (US)
Tel.: +1-855-463-3463
Email: medinfo@incyte.com
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Does vitiligo increase the risk of skin cancer?
No, it does not. Despite common misconceptions, people with vitiligo are actually at a lower risk of developing skin cancer—including both nonmelanoma skin cancer (NMSC) and mal...
- What is the best therapy for localized vitiligo?
Localized vitiligo, where the white patches are limited to one or a few areas of the body, can be managed with a few treatment approaches. The best therapy usually depends on th...
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.